By PPN News Staff
The FDA approved fostemsavir (Rukobia, ViiV Healthcare) to treat adults with multidrug resistance (MDR) HIV, whose viral loads are not reduced despite taking multiple HIV medications.
Fostemsavir, provided as 600 mg extended-release tablets, is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use with other antiretroviral therapies (ART) in heavily treatment-experienced adults with MDR HIV-1 infection, who are failing their current ART due to